kt 5823 has been researched along with cyclin d1 in 1 studies
Studies (kt 5823) | Trials (kt 5823) | Recent Studies (post-2010) (kt 5823) | Studies (cyclin d1) | Trials (cyclin d1) | Recent Studies (post-2010) (cyclin d1) |
---|---|---|---|---|---|
317 | 0 | 59 | 10,885 | 70 | 5,157 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ren, Y; Weng, G; Wu, L; Yao, X; Zheng, J | 1 |
1 other study(ies) available for kt 5823 and cyclin d1
Article | Year |
---|---|
Essential role of the cGMP/PKG signaling pathway in regulating the proliferation and survival of human renal carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Carbazoles; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Gene Expression Regulation; Humans; JNK Mitogen-Activated Protein Kinases; Phosphodiesterase 5 Inhibitors; Phosphorylation; Signal Transduction; Sp1 Transcription Factor; Sulindac | 2014 |